Citigroup
DRMA icon

Citigroup’s Dermata Therapeutics DRMA Stock Holding History

Citigroup’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$1 – 5853
2026
Q1 		$1 Buy
+1
New +$2 ﹤0.01% 5856
2025
Q3 		– Sell
-6
Closed -$35 – 6149
2025
Q2 		$35 Buy
+6
New +$46 ﹤0.01% 5548
2022
Q3 		– Sell
-20
Closed -$32K – 5939
2022
Q2 		$32K Buy
+20
New +$41.2K ﹤0.01% 4752

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AA
Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Citigroup's DRMA Position: Q2 2026 in Review

Citigroup sold out of Dermata Therapeutics (DRMA) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in DRMA in Q2 2022 and held it in 3 quarters. The position peaked at $32K in Q2 2022. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

  • Citigroup reported no remaining Dermata Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Dermata Therapeutics share in Q2 2026, an estimated $1.
  • Citigroup first reported a position in Dermata Therapeutics in Q2 2022 and held it in 3 quarters.
  • Citigroup's Dermata Therapeutics position peaked at $32K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.